These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

983 related items for PubMed ID: 10397264

  • 1. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
    Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marmé D, Martiny-Baron G.
    Cancer Res; 1999 Jul 01; 59(13):3185-91. PubMed ID: 10397264
    [Abstract] [Full Text] [Related]

  • 2. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
    Shibuya M, Seetharam L, Ishii Y, Sawano A, Gotoh N, Matsushime H, Yamaguchi S.
    Princess Takamatsu Symp; 1994 Jul 01; 24():162-70. PubMed ID: 8983073
    [Abstract] [Full Text] [Related]

  • 3. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, Zhu Z.
    Cancer Res; 2001 Oct 01; 61(19):7002-8. PubMed ID: 11585724
    [Abstract] [Full Text] [Related]

  • 4. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.
    Cancer Res; 2000 Apr 15; 60(8):2178-89. PubMed ID: 10786682
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM.
    Medicina (B Aires); 2000 Apr 15; 60 Suppl 2():41-7. PubMed ID: 11188930
    [Abstract] [Full Text] [Related]

  • 6. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ.
    Clin Cancer Res; 2000 Mar 15; 6(3):957-65. PubMed ID: 10741721
    [Abstract] [Full Text] [Related]

  • 7. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
    Shiose S, Sakamoto T, Yoshikawa H, Hata Y, Kawano Y, Ishibashi T, Inomata H, Takayama K, Ueno H.
    Invest Ophthalmol Vis Sci; 2000 Aug 15; 41(9):2395-403. PubMed ID: 10937546
    [Abstract] [Full Text] [Related]

  • 8. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development.
    Breier G, Clauss M, Risau W.
    Dev Dyn; 1995 Nov 15; 204(3):228-39. PubMed ID: 8573716
    [Abstract] [Full Text] [Related]

  • 9. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases.
    Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M.
    Cancer Res; 2001 Mar 01; 61(5):2145-53. PubMed ID: 11280779
    [Abstract] [Full Text] [Related]

  • 10. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.
    Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Büttner M, Rziha HJ, Dehio C.
    EMBO J; 1999 Jan 15; 18(2):363-74. PubMed ID: 9889193
    [Abstract] [Full Text] [Related]

  • 11. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Nakatani T, Tsujinoue H, Fukui H.
    Hepatology; 1999 Nov 15; 30(5):1179-86. PubMed ID: 10534339
    [Abstract] [Full Text] [Related]

  • 12. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1).
    Yamane A, Seetharam L, Yamaguchi S, Gotoh N, Takahashi T, Neufeld G, Shibuya M.
    Oncogene; 1994 Sep 15; 9(9):2683-90. PubMed ID: 8058332
    [Abstract] [Full Text] [Related]

  • 13. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.
    Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, Watanabe Y, Pass HI.
    Br J Cancer; 1999 Sep 15; 81(1):54-61. PubMed ID: 10487612
    [Abstract] [Full Text] [Related]

  • 14. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
    Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N.
    Cancer Res; 2000 Apr 15; 60(8):2169-77. PubMed ID: 10786681
    [Abstract] [Full Text] [Related]

  • 15. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis.
    Valter MM, Hügel A, Huang HJ, Cavenee WK, Wiestler OD, Pietsch T, Wernert N.
    Cancer Res; 1999 Nov 01; 59(21):5608-14. PubMed ID: 10554042
    [Abstract] [Full Text] [Related]

  • 16. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE.
    Cancer Res; 2000 Sep 15; 60(18):5117-24. PubMed ID: 11016638
    [Abstract] [Full Text] [Related]

  • 17. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
    Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, Fox SB.
    Clin Cancer Res; 2000 Nov 15; 6(11):4278-86. PubMed ID: 11106244
    [Abstract] [Full Text] [Related]

  • 18. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.
    Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzog C, Marmé D.
    Cancer Res; 1997 Dec 01; 57(23):5421-5. PubMed ID: 9393770
    [Abstract] [Full Text] [Related]

  • 19. Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells.
    Ahmed A, Dunk C, Kniss D, Wilkes M.
    Lab Invest; 1997 Jun 01; 76(6):779-91. PubMed ID: 9194854
    [Abstract] [Full Text] [Related]

  • 20. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
    Belletti B, Ferraro P, Arra C, Baldassarre G, Bruni P, Staibano S, De Rosa G, Salvatore G, Fusco A, Persico MG, Viglietto G.
    Oncogene; 1999 Aug 26; 18(34):4860-9. PubMed ID: 10490819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.